Skip to content


  • Case report
  • Open Access

Necrolytic migratory erythema as the first manifestation of pancreatic neuroendocrine tumor

World Journal of Surgical Oncology201412:220

  • Received: 16 April 2014
  • Accepted: 4 July 2014
  • Published:


Necrolytic migratory erythma (NME) is an obligatory paraneoplastic syndrome. Here we describe a woman admitted to the dermatology ward with NME which was later found to be associated with glucagonoma, a slow-growing, rare pancreatic neuroendocrine tumor. Even more rarely, the tumor was located in the pancreas head, while most of such lesions are located in the distal pancreas. The diagnosis of this rare tumor requires an elevated serum glucagon level and imaging confirming a pancreatic tumor. After surgical removal of the tumor, the patient’s cutaneous and systemic features resolved. It is therefore imperative that clinicians recognize NME early in order to make an accurate diagnosis and to provide treatment for this rare tumor.


  • Necrolytic migratory erythema
  • Glucagonoma
  • Pancreatic neuroendocrine tumors


Necrolytic migratory erythema (NME) is a rare skin disorder which was first described by Becker et al. in 1942[1]. Erythematous scaly lesions with centrifugal growth characterize the clinical appearance of the disease. Perineum, distal extremities, lower abdomen, and face are the most commonly affected sites[2]. NME is an obligatory paraneoplastic syndrome. Most of NME cases are associated with pancreatic neuroendocrine tumors (PNETs). PNETs are rare neoplasms representing <5% of all pancreatic malignancies with an estimated incidence of 1 to 1.5 cases/100,000[3] and are classified by the hormonal products that they produce. Glucagonomas, considered among the rarest of PNETs, produce a well defined clinical syndrome characterized by NME, diabetes mellitus, glossitis, anemia, and weight loss[4]. In this paper, we describe a woman admitted to the dermatology ward with NME, which was later found to be associated with glucagonoma located at the head of the pancreas. We will describe NME, the glucagonoma syndrome and how to recognize and treat this rare tumor.

Case presentation

A 44-year-old woman presented with a 3-month history of pruritic rash of the extremities and oral cavity. The rash progressed to involve the groin, abdomen, axillae, and gluteal region. She was found to have well demarcated, erythematous plaques in these regions. Tiny fragile vesicles were observed at the margins of several plaques (Figure 1). At this time, the patient was admitted to the dermatology ward for further evaluation. The patient underwent allergen patch testing, which was negative, and was treated with topical steroids without clinical improvement. Skin biopsy revealed psoriasiform acanthosis and abrupt necrosis of the upper layers of stratum; whereas the lower half of epidermis appears viable, the detached necrolytic portion appears pale with pyknotic nuclei. Perivascular lymphocytic infiltration and scattered extravasated red blood cells were present in the upper dermis.
Figure 1
Figure 1

Close-up view of well demarcated erythematous plaques, with fragile vesicles on gluteal area.

Based on these findings, NME was considered. A glucagon level was obtained and a contrast-enhanced CT scan was conducted. Her level of serum glucagon was elevated at 720 ng/L (normal values 40 to 130 ng/L) (Table 1) and the scan revealed a 3-cm enhancing pancreatic head mass (Figure 2). Thus, a referral to the hepatobiliary department was made.
Table 1

Laboratory values on the day of hospital admission and hospital day 14 (post-operative day 7)

Serum laboratory studies

Admission values

Post-operative values

Normal values

Glucose (mg/dL)




Glucagon (ng/L)




Chromogranin A (ng/mL)




Glycosylated hemoglobin (%)




Figure 2
Figure 2

Contrast-enhanced computed tomography scan of the abdomen. A 3-cm nodular mass in the head of the pancreas was seen. There was no evidence of metastases.

On admission, she had stable vital signs. Admission laboratory measurements demonstrated hyperglycemia (132 mg/dL, normal values 60 to 99 mg/dL) and anemia (hemoglobin 11.4, normal values 12 to 16 g/dL). Serum levels of chromogranin A, a tumor marker for neuroendocrine tumors, were elevated (243 ng/mL, normal value <96 ng/mL), as were levels of glycosylated hemoglobin (6.3%, normal value <5.7%) and the patient was diagnosed with diabetes mellitus.

On hospital day 7, she underwent pancreaticoduodenectomy. Pathology confirmed a pancreatic neuroendocrine carcinoma with evidence of vascular and perineural invasion, consistent with a diagnosis of a glucagonoma. In the days following her operation, the patient was admitted to the ICU, where she faced pancreatic fistula that resolved with non-operative care. Her glucagon and glucose blood levels dropped dramatically post-operatively (Table 1). One week after the surgery, the patient's cutaneous lesions almost disappeared. Currently, more than 1 year post-operatively, there was no sign of cutaneous or systemic disease.


Glucagonoma is a slow growing PNET, which is often heralded by paraneoplastic phenomena. The key features of the glucagonoma syndrome, a rare disorder with an estimated incidence of 1 in 20 million[5], are NME and diabetes mellitus[6]. Other common manifestations include weight loss, stomatitis, steatorrhea, diarrhea, thromboembolic tendency, anemia, and neuropsychiatric features[7]. Males and females are equally affected, with an age peak presentation in the fifth decade of life[8]. The diagnosis of a glucagonoma requires an elevated serum glucagon level and imaging confirming a pancreatic tumor. Unfortunately, delays in diagnosis are common for this slow growing tumor. It may proceed at least 1 year before a correct diagnosis is made[9]. At least half of patients will have metastatic disease when diagnosed[10]. Delays in diagnosis have been attributed to the extreme rarity of the tumor, under-recognition of the dermatologic presentation, the difficulty making the diagnosis of NME on biopsy, and the lack of specificity of the other symptoms[11].

NME is the most specific feature of the syndrome, and is the presenting symptom in approximately 70% of patients[9]. The exact cause of NME remains unknown. Although normalization of glucagon level by resection of the tumor usually results in a rapid disappearance of the skin disorder[12], elevation of serum glucagon levels alone cannot explain all of the skin findings, since hyperglucagonemia occurring in other situations, such as trauma, burns, diabetic ketoacidosis starvation and cirrhosis, does not lead to a typical rash[13]. Hypoaminoacidemia or other nutritional deficiencies, such as essential fatty acids or zinc, might also contribute to the occurrence of NME because of the cutaneous histologic similarities between these deficiency states and this syndrome[14, 15]. The early recognition and correct diagnosis of NME is important because it can be the only and the first manifestation of the glucagonoma syndrome. However, the correct diagnosis of NME is challenging as the lesions of the NME may be often misinterpreted as contact dermatitis, intertrigo, inverse psoriasis, zinc deficiency, and other nutritional deficiencies[7].

Diabetes mellitus is another common finding. Glucagon has many important effects on glucose metabolism. It stimulates hepatic gluconeogenesis, inhibits glycolysis and glycogen synthesis. Case studies suggest that 80% of patients with glucagonomas will eventually develop the disease[12].

Glucagonomas are typically distal pancreatic tumors, generally large in size due to late detection, often measuring between 4 and 10 cm[16]. However, the tumor in our patient was located in the head of the pancreas, which is uncommon for this disease. Moreover, the tumor was detected in its early stage due to the prompt and accurate diagnosis.

Contrast-enhanced CT is recommended to identify the number and location of tumors. Somatostatin receptor scintigraphy may be obtained if there is concern for distant disease[17]. The best and the most effective treatment strategy should aim to lower serum glucagon levels. A complete resection of the tumor is the best option because of its weak response to chemotherapy[14]. Patients who underwent resection had significantly longer median survival than patients who did not receive surgery, even when diagnosed with later stages of disease[18].




computed tomography


necrolytic migratory erythma


pancreatic neuroendocrine tumor.


Authors’ Affiliations

Department of Hepatobiliary Surgery, the First Affiliated Hospital of Xi’an Jiaotong University School of Medicine, No. 277, Yanta West Road, 710061 Xi’an, Shaanxi, P.R. China


  1. Becker SW, Brennan BB: Benign and malignant cutaneous tumors in the elderly. Arch Dermatol. 1961, 83: 262-271. 10.1001/archderm.1961.01580080092010.View ArticlePubMedGoogle Scholar
  2. Afsharfard A, Atqiaee K, Lotfollahzadeh S, Alborzi M, Derakhshanfar A: Necrolytic migratory erythema as the first manifestation of glucagonoma. Case Rep Surg. 2012, 2012: 974210-PubMed CentralPubMedGoogle Scholar
  3. Batcher E, Madaj P, Gianoukakis AG: Pancreatic neuroendocrine tumors. Endocr Res. 2011, 36: 35-43. 10.3109/07435800.2010.525085.View ArticlePubMedGoogle Scholar
  4. Edney JA, Hofmann S, Thompson JS, Kessinger A: Glucagonoma syndrome is an underdiagnosed clinical entity. Am J Surg. 1990, 160: 625-628. 10.1016/S0002-9610(05)80761-5.View ArticlePubMedGoogle Scholar
  5. Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV: The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine. 1996, 75: 53-63. 10.1097/00005792-199603000-00002.View ArticlePubMedGoogle Scholar
  6. Johnson SM, Smoller RB, Lamps LW, Horn TD: Necrolytic migratory erythema as the only presenting sign of a glucagonoma. J Am Acad Dermatol. 2003, 49: 325-328. 10.1067/S0190-9622(02)61774-8.View ArticlePubMedGoogle Scholar
  7. Lobo I, Carvalho A, Amaral C, Machado S, Carvalho R: Glucagonoma syndrome and necrolytic migratory erythema. Int J Dermatol. 2010, 49: 24-29. 10.1111/j.1365-4632.2009.04220.x.View ArticlePubMedGoogle Scholar
  8. Doherty GM: Rare endocrine tumours of the GI tract. Best Pract Res Clin Gastroenterol. 2005, 19: 807-818. 10.1016/j.bpg.2005.05.004.View ArticlePubMedGoogle Scholar
  9. Eldor R, Glaser B, Fraenkel M, Doviner V, Salmon A, Gross DJ: Glucagonoma and the glucagonoma syndrome - cumulative experience with an elusive endocrine tumour. Clin Endocrinol. 2011, 74: 593-598. 10.1111/j.1365-2265.2011.03967.x.View ArticleGoogle Scholar
  10. Echenique-Elizondo M, Tuneu Valls A, Elorza Orúe JL, Martinez De Lizarduy I, Ibáñez Aguirre J: Glucagonoma and pseudoglucagonoma syndrome. JOP. 2004, 5: 179-185.PubMedGoogle Scholar
  11. Halvorson SA, Gilbert E, Hopkins RS, Liu H, Lopez C, Chu M, Martin M, Sheppard B: Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome. J Gen Intern Med. 2013, 28: 1525-1529. 10.1007/s11606-013-2490-5.PubMed CentralView ArticlePubMedGoogle Scholar
  12. Van Beek AP, De Haas ER, Van Vloten WA, Lips CJ, Roijers JF, Canninga-van Dijk MR: The glucagonoma syndrome and necrolytic migratory erythema: a clinical review. Eur J Endocrinol. 2004, 151: 531-537. 10.1530/eje.0.1510531.View ArticlePubMedGoogle Scholar
  13. Adam DN, Cohen PD, Ghazarian D: Necrolytic migratory erythema: case report and clinical review. J Cutan Med Surg. 2003, 7: 333-338. 10.1007/s10227-002-0127-0.View ArticlePubMedGoogle Scholar
  14. Alexander EK, Robinson M, Staniec M, Dluhy RG: Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome. Clin Endocrinol. 2002, 57: 827-831. 10.1046/j.1365-2265.2002.01660.x.View ArticleGoogle Scholar
  15. Chastain MA: The glucagonoma syndrome: a review of its features and discussion of new perspectives. Am J Med Sci. 2001, 321: 306-320. 10.1097/00000441-200105000-00003.View ArticlePubMedGoogle Scholar
  16. Akerström G, Hellman P: Surgical aspects of neuroendocrine tumours. Eur J Cancer. 2009, 45: 237-250.View ArticlePubMedGoogle Scholar
  17. Sundin A, Garske U, Orlefors H: Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007, 21: 69-85. 10.1016/j.beem.2006.12.003.View ArticlePubMedGoogle Scholar
  18. Hill JS, McPhee JT, McDade TP, Zhou Z, Sullivan ME, Whalen GF, Tseng JF: Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer. 2009, 115: 741-751. 10.1002/cncr.24065.View ArticlePubMedGoogle Scholar


© Wu et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.